PROTALIX BIOTHERAPEUTICS, INC. Protalix BioTherapeutics, Inc. Share Price
Equities
PLX
US74365A3095
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.15 USD | -2.54% |
|
0.00% | -35.39% |
| 14/03 | Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024 | |
| 14/03 | Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2024 * | 74.06M 6.17B | Sales 2025 * | 127M 10.62B | Capitalization | 84.01M 7B |
|---|---|---|---|---|---|
| Net income 2024 * | 17M 1.42B | Net income 2025 * | 70M 5.84B | EV / Sales 2024 * | 1.13 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 0.66 x |
| P/E ratio 2024 * |
5.48
x | P/E ratio 2025 * |
1.42
x | Employees | 208 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.23% |
More Fundamentals
* Assessed data
More news
Latest transcript on Protalix BioTherapeutics, Inc.
More press releases
| 1 day | -2.54% | ||
| Current month | -8.73% | ||
| 1 month | -8.00% | ||
| 3 months | -22.30% | ||
| 6 months | -19.58% | ||
| Current year | -35.39% |
1 week
1.09
1.24
1 month
1.091.35
Current year
1.091.85
1 year
1.093.55
3 years
0.703.91
5 years
0.707.02
10 years
0.7042.00
| Managers | Title | Age | Since |
|---|---|---|---|
Dror Bashan
CEO | Chief Executive Officer | 57 | 30/19/30 |
Eyal Rubin
DFI | Director of Finance/CFO | 48 | 22/19/22 |
Yael Hayon
CTO | Chief Tech/Sci/R&D Officer | 41 | 05/20/05 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Pol Boudes
BRD | Director/Board Member | 67 | 01/19/01 |
Gwen Melincoff
BRD | Director/Board Member | 72 | 01/19/01 |
Aharon Schwartz
BRD | Director/Board Member | 80 | 01/14/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.15 | -2.54% | 958,735 |
| 25/24/25 | 1.18 | -2.48% | 192,155 |
| 24/24/24 | 1.21 | +0.83% | 228,353 |
| 23/24/23 | 1.2 | +1.69% | 272,095 |
| 22/24/22 | 1.18 | +2.61% | 225,065 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotes
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
1.15
USD
Average target price
13
USD
Spread / Average Target
+1,030.43%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -35.39% | 84.01M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- PLX Stock
